RT Journal Article
SR Electronic
T1 Recombinant adjuvanted zoster vaccine and reduced risk of COVID-19 diagnosis and hospitalization in older adults
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.10.01.21264400
DO 10.1101/2021.10.01.21264400
A1 Katia J. Bruxvoort
A1 Bradley Ackerson
A1 Lina S. Sy
A1 Amit Bhavsar
A1 Hung Fu Tseng
A1 Ana Florea
A1 Yi Luo
A1 Yun Tian
A1 Zendi Solano
A1 Robyn Widenmaier
A1 Meng Shi
A1 Robbert Van Der Most
A1 Johannes Eberhard Schmidt
A1 Jasur Danier
A1 Thomas Breuer
A1 Lei Qian
YR 2021
UL http://medrxiv.org/content/early/2021/10/03/2021.10.01.21264400.abstract
AB Background Vaccines may elicit long-term boosting of innate immune responses that can help protect against COVID-19. We evaluated the association between recombinant adjuvanted zoster vaccine (RZV) and COVID-19 outcomes at Kaiser Permanente Southern California.Methods In a cohort design, adults aged ≥50 years who received ≥1 RZV dose prior to 3/1/2020 were matched 1:2 to unvaccinated individuals and followed until 12/31/2020. Adjusted hazard ratios (aHR) and 95% confidence intervals (CIs) for COVID-19 outcomes were estimated using Cox proportional hazards regression. In a test-negative design, cases had a positive SARS-CoV-2 test and controls had only negative tests, from 3/1/2020-12/31/2020. Adjusted odds ratios (aOR) and 95% CIs for prior receipt of RZV were estimated using logistic regression.Results In the cohort design, 149,244 RZV recipients were matched to 298,488 unvaccinated individuals. The aHRs (95% CI) for COVID-19 diagnosis and hospitalization were 0.84 (0.81-0.87) and 0.68 (0.64-0.74), respectively. In the test-negative design, 8.4% of 75,726 test-positive cases and 13.1% of 340,898 test-negative controls had received ≥1 RZV dose. The aOR (95% CI) was 0.84 (0.81-0.86).Conclusion RZV vaccination was associated with a 16% lower risk of COVID-19 diagnosis and 32% lower risk of hospitalization, suggesting RZV elicits heterologous protection, possibly through trained immunity.Competing Interest StatementDr. Ackerson, Dr. Bruxvoort, Dr. Florea, Dr. Luo, Dr. Qian, Ms. Solano, Ms. Sy, Ms. Tian, and Dr. Tseng received research funding from the GSK group of companies for work related to this paper. Dr. Ackerson, Dr. Bruxvoort, Dr. Qian, Ms. Solano, and Ms. Sy received research funding from Dynavax for work unrelated to this paper. Dr. Ackerson, Dr. Bruxvoort, Dr. Luo, Ms. Sy, and Dr. Tseng received research funding from Seqirus for work unrelated to this paper. Dr. Bruxvoort, Dr. Florea, and Ms. Solano received research funding from Gilead for work unrelated to this paper. Dr. Ackerson, Dr. Bruxvoort, Dr. Florea, Dr. Luo, Dr. Qian, Ms. Sy, Ms. Tian, and Dr. Tseng received research funding from Moderna for work unrelated to this paper. Dr. Ackerson, Dr. Bruxvoort, and Dr. Florea received research funding from Pfizer for work unrelated to this paper. KPSC received fees for consultation work with Johnson and Johnson by Dr. Tseng. Dr. Bhavsar, Ms. Widenmaier, Mr. Shi, Dr. Van Der Most, Dr. Schmidt, Dr. Danier, and Dr. Breuer were employees of the GSK group of companies at the time of the study conduct. Ms. Widenmaier, Dr. Van Der Most, Dr. Schmidt, Dr. Danier, and Dr. Breuer hold shares in the GSK group of companies. All authors do not have any non-financial relationships and activities to declare. This work was supported by GlaxoSmithKline Biologicals SA. Costs associated with manuscript editorial and coordination support were covered by GlaxoSmithKline Biologicals SA. The authors thank the members of Kaiser Permanente for helping to improve care through the use of information collected through our electronic health record systems. Editorial and coordination support was provided by Adrian Kremer (Modis c/o GSK).Clinical TrialThis is a non-interventional observational trial that has been registered on the GSK-registry trial postingFunding StatementThis work was supported by GlaxoSmithKline Biologicals SA. Costs associated with manuscript editorial and coordination support were covered by GlaxoSmithKline Biologicals SA. The authors thank the members of Kaiser Permanente for helping to improve care through the use of information collected through our electronic health record systems. Editorial and coordination support was provided by Adrian Kremer (Modis c/o GSK).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Kaiser Permanente Southern California (KPSC) Institutional Review Board reviewed and approved the study with a waiver for the requirement of informed consentAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe study details (GSK study number 217021) are available on the GSK Clinical Study Register and can be accessed at www.gskclinicalstudyregister.com. https://www.gsk-studyregister.com/en/trial-details/?id=217021